Maybe someone better informed can explain why this isn't even remotely possible? I think antibodies have half lives, but some autoimmune disorders are persistent (arthritis, lupus, MS, etc).
> Given the high verification rate of reports of myocarditis to VAERS after mRNA-based COVID-19 vaccination, underreporting is more likely. Therefore, the actual rates of myocarditis per million doses of vaccine are likely higher than estimated.
Here, in Ontario, Canada, till Jan 16, 2022:
https://www.publichealthontario.ca/-/media/documents/ncov/ep...
> "The highest reporting rate was observed for males aged 18- 24 years of age following dose 2, at 193.8 events per million doses administered."
And this pre-print says that while "the risk of hospital admission or death from myocarditis is greater following COVID-19 infection than following vaccination", however "the risk of myocarditis following vaccination is consistently higher in younger males, particularly following a second dose of RNA mRNA-1273 vaccine."
Aka, risk of myocarditis for men under 40 years old is consistently higher from the shots than from infection.
https://www.medrxiv.org/content/10.1101/2021.12.23.21268276v...
While this last link is a preprint, in the "Main" section of the pre-print, the authors note that this preprint is an update to their previous Nature article:
> "Our recent article on the association between COVID-19 vaccination and myocarditis generated considerable scientific, policy and public interest [1]. It added to evidence emerging from multiple countries that have linked exposure to BNT162b2 messenger RNA vaccine with acute myocarditis [2-8] .In the largest and most comprehensive analysis to date, we confirmed prior findings and reported an increase in hospital admission or death from myocarditis following three different types of vaccine including both mRNA and adenoviral vaccines. Importantly, we also demonstrated that across the entire vaccinated population in England, the risk of myocarditis following vaccination was small compared to the risk following a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test [1]. However, myocarditis is more common in younger persons and in males in particular [9, 10]. Additional analyses stratified by both age and sex and following a third vaccine dose were requested as vaccine campaigns are rapidly being extended to include children and young adults. Furthermore, given the consistent observation that the risk of myocarditis is higher following the second dose of vaccine compared to the first dose [1, 11], there is an urgent need to evaluate the risk associated with a third dose as booster programmes are accelerated internationally to combat the omicron variant [12]."
